<SUBMISSION>
<ACCESSION-NUMBER>0001144204-06-028627
<TYPE>6-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20060717
<FILING-DATE>20060717
<DATE-OF-FILING-DATE-CHANGE>20060717
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>3826
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>06963801
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v047655_6k.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><a name="return"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></a></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 16pt; FONT-FAMILY: Times New Roman"><strong>FORM
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT
      OF
      FOREIGN ISSUER</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to Rule 13a-16 or 15d-16 of</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
      Securities Exchange Act of 1934</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>For
      the month of July 2006</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commission
      File Number 000-5112</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>pSivida
      Limited</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant&#8217;s name into English) </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level
      12
      BGC Centre</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28
      The
      Esplanade</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth
      WA
      6000</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form&#160;20-F or Form&#160;40-F). </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      20-F
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form
      40-F </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant by furnishing the information contained
      in
      this Form is also thereby furnishing the information to the Commission pursuant
      to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      "Yes"
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule&#160;12g3-2(b): 82- ___. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURE
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, the registrant,
      pSivida Limited, has duly caused this report to be signed on its behalf by
      the
      undersigned, thereunto duly authorized. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
      July 17, 2006</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr valign="top" bgcolor="#ffffff">
            <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">pSivida
              Limited</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td>&#160;</td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">/s/
              Aaron Finlay</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
            <td align="left">
              <hr style="COLOR: black" align="left" noshade size="2" width="80%"><font size="2">Aaron
              Finlay</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: "><em>Company
              Secretary</em></font></td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>EXHIBIT
      INDEX</u></em></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EXHIBIT
                99.1:</strong></font></div>
            </td>
            <td align="left" valign="top" width="62%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSivida
                amends subordinated convertible debentures</strong></font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">&#160;</td>
            <td align="left" valign="top" width="62%">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v047655_ex99-1.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right">
<IMG SRC="psivida_logo.jpg">
</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #ff0000; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="justify" valign="top" width="40%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ASX/MEDIA
                RELEASE</strong></font></div>
            </td>
            <td align="right" valign="top" width="40%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><strong>17
                July 2006</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 16pt; FONT-FAMILY: Times New Roman"><strong>pSivida
      amends subordinated convertible debentures</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
      <div>
        <hr style="COLOR: black" align="left" noshade size="1" width="100%">
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Boston,
      MA. and Perth, Australia - Global bio-nanotech company pSivida Limited (ASX:PSD,
      NASDAQ:PSDV, Xetra:PSI) has today signed a term sheet with Sandell Asset
      Management Corporation, investment advisor to Castlerigg Master Investments
      (the
      Note Holder) to revise the terms of the Note Holder&#8217;s US$15,000,000 subordinated
      convertible debentures (the Notes).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Notes
      will continue to have a three year term and bear 8% interest payable quarterly.
      The Company may, at its sole discretion, choose to make interest payments in
      cash and/or the Company&#8217;s NASDAQ listed American Depositary Receipt Securities
      (ADSs). The Note Holder will retain its existing warrants to purchase
      approximately 633,000 additional ADSs. Those warrants are exercisable for six
      years at a current exercise price of US$7.17 per ADS (AU$0.98 per ordinary
      share).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      amended terms, which are subject to the completion of definitive documentation,
      consist of the following:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 18pt;">&#160;</td>
            <td style="width: 18pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                Notes will be secured by the Company&#8217;s current royalties, subject to
                release of that security upon any disposition by the Company of the
                royalty stream and the consequent collateral partial payment of the
                Notes.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 18pt;">&#160;</td>
            <td style="width: 18pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                existing conversion price on the Notes will be reset to US$2.00 per
                ADS,
                subject to anti-dilution adjustments relating to future share issuances
                by
                the Company, if any, and will be reset based on the market price,
                if
                lower, on April 30, 2007.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 18pt;">&#160;</td>
            <td style="width: 18pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                Note Holder will have an option to have up to US$6.25&#160;million of the
                Notes redeemed on each of July 31, 2007 and January 31, 2008, with
                the
                original 15 November 2006 put option and subsequent put options being
                struck from the Notes.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 18pt;">&#160;</td>
            <td style="width: 18pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                Company may redeem all or any part of the Notes at any time at its
                option
                at 108% face value accompanied by an additional five year warrant
                for 30%
                of the redemption amount with an exercise price equal to the lower
                of the
                conversion price or 75% of the then market price. This new term permits
                refinancing by the Company at any
                time.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 18pt;">&#160;</td>
            <td style="width: 18pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                existing minimum cash retention requirement will be struck from the
                Notes
                upon the later of aggregate capital raisings of US$15&#160;million or
                effectiveness of the registration statement filed with US Securities
                and
                Exchange Commission (SEC) relating to the Notes and warrants (Registration
                Statement).</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      connection with the amendments, the Company has agreed with the investor as
      follows:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 18pt;">&#160;</td>
            <td style="width: 18pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                Company will have a further 60 days for the Registration Statement
                to be
                declared effective by the SEC, with increased penalties if that deadline
                is missed, subject to the completion of definitive documentation
                concerning the amendments by 21
                July.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 18pt;">&#160;</td>
            <td style="width: 18pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                investor will release the Company from any restrictions involving
                future
                fundraising efforts maintaining only its right to participate in
                exchange
                for redemption of Notes.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 18pt;">&#160;</td>
            <td style="width: 18pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                Company will grant the Note Holder an additional warrant over
                approximately 5.7&#160;million&#160;ADSs exercisable for five years with
                US$1.80 per ADS strike price.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td style="width: 18pt;">&#160;</td>
            <td style="width: 18pt;">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                Company will prepay US$2.5&#160;million of the existing debt prior to the
                end of the term of the Notes by means of a US$3.5&#160;million
                payment.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;These
      actions taken by the Company free the Company to continue the development of
      its
      technology and products without some of the future financial risks and
      restrictions it had previously under these Notes,&#8221; said Gavin Rezos, CEO of
      pSivida Limited. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;The
      Company is making operational changes to bring about significant cost savings
      to
      make more efficient use of our resources, in particular making better use of
      our
      Boston facilities and in keeping with our strategy of moving corporate functions
      to Boston. Focus will be shifted from any early stage or non-core research
      and
      development to completion of late stage clinical trials and subsequent expected
      commercial returns. Non core areas and early stage programs will only be
      undertaken with external funding from research or development partners,&#8221; said Mr
      Rezos.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;The
      Company also has externally funded and self funded programs with biotech
      companies and large pharmaceutical companies, including evaluation programs
      with
      four of the top five large pharmaceutical companies to evaluate the use of
      our
      drug delivery technologies to deliver therapeutic compounds of those companies.
      Some of these evaluation agreements may lead to Licensing arrangements,&#8221; Mr
      Rezos added.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company&#8217;s core focus is the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">development
      of drug delivery products</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      in the
      healthcare sector, particularly in Ophthalmology and Oncology. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">owns
      the
      rights to develop and commercialize a modified form (porosified or
      nano-structured) of silicon known as BioSilicon&#8482; which we believe has versatile
      applications in drug delivery. The lead BioSilicon&#8482; product in oncology is
      BrachySil&#8482;, a brachytherapy product in pivotal Phase IIb clinical trials, which
      is being developed for the treatment of inoperable primary liver cancer and
      in a
      soon to commence phase IIa clinical trial in pancreatic cancer. The Company
      has
      a licensing agreement with Beijing Med-Pharm Corporation for the clinical
      development, marketing and distribution of BrachySil&#8482; in China. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company receives royalties from the sale of its Ophthalmology products,
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Vitrasert</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><sup>&#174;</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      and
      Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      the
      only two FDA approved sustained release back of the eye treatments for chronic
      eye disease. Both products are manufactured and sold by global ophthalmology
      company, Bausch &amp; Lomb (B&amp;L). Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      is also
      promoted by Novartis Ophthalmic, a business unit of Novartis Pharmaceuticals,
      in
      collaboration with B&amp;L. A next generation product, Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      in Phase
      III clinical trials, is licensed to Alimera Sciences for the treatment of
      Diabetic Macular Edema, the leading cause of vision loss for Americans under
      the
      age of 65.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Wholly-owned
      subsidiary, AION Diagnostics Inc. recently announced that BioSilicon&#8482; has been
      shown to be effectively visualized on four key imaging modalities; x-ray,
      ultrasound, CT and MRI. This discovery could eventually lead to AION Diagnostics
      being competitively positioned in the multi-billion dollar imaging agent market.
      It is expected that AION Diagnostics will be a separately funded independent
      entity in the near term. pSivida will receive royalty payments from AION
      Diagnostics on successfully commercialised BioSilicon&#8482; diagnostic products under
      Licence from pSivida.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      announcement does not constitute an offer of any securities for sale or the
      solicitation of an offer to buy any securities. The securities offered have
      not
      been registered under the U.S. Securities Act of 1933, as amended, and may
      not
      be offered or sold in the United States absent registration or an applicable
      exemption from registration requirements.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><strong>-ENDS-</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="26%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSivida
                Limited</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Brian
                Leedman</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor
                Relations</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                Limited</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                + 61 8 9226 5099</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">brianl@psivida.com</font></div>
            </td>
            <td align="left" valign="top" width="26%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>US
                Public Relations</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beverly
                Jedynak</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">President</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Martin
                E. Janis &amp; Company, Inc</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                +1 (312) 943 1100 ext. 12</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">bjedynak@janispr.com</font></div>
            </td>
            <td align="left" valign="top" width="26%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>European
                Public Relations</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Eva
                Reuter</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                +49 (254) 393 0740</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">e.reuter@e-reuter-ir.com</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>NOTES
      TO EDITORS: </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">pSivida
      is a global bio-nanotech company committed to the biomedical sector and the
      development of drug delivery products. Retisert&#8482; is FDA approved for the
      treatment of uveitis. Vitrasert&#174; is FDA approved for the treatment of
      AIDS-related CMV Retinitis. Bausch &amp; Lomb own the trademarks Vitrasert&#174; and
      Retisert&#8482;. pSivida has licensed the technologies underlying both of these
      products to Bausch &amp; Lomb. The technology underlying Medidur&#8482;, a treatment
      for diabetic macular edema, is licensed to Alimera Sciences and is in Phase
      III
      clinical trials.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">pSivida
      owns the rights to develop and commercialise a modified form of silicon
      (porosified or nano-structured silicon) known as BioSilicon&#8482;, which has
      applications in drug delivery, wound healing, orthopaedics, and tissue
      engineering. pSivida&#8217;s subsidiary, AION Diagnostics Limited is developing
      diagnostic products and the subsidiary pSiNutria is developing food technology
      products both using BioSilicon&#8482;. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">pSivida&#8217;s
      intellectual property portfolio consists of 70 patent families, 74 granted
      patents and over 290 patent applications.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">
      pSivida conducts its operations from offices and facilities near Boston in
      the
      United States, Malvern in the United Kingdom, Perth in Australia and Singapore.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">pSivida
      is listed on NASDAQ (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><strong>PSDV</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">),
      the Australian Stock Exchange (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><strong>PSD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">)
      and on the Frankfurt Stock Exchange on the XETRA system (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><strong>German</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><strong>Symbol:
      PSI. Securities Code (WKN) 358705</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">).
      pSivida is a founding member of the NASDAQ Health Care Index and the Merrill
      Lynch Nanotechnology Index.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">The
      Company's largest shareholder and a strategic partner is QinetiQ, a leading
      international defence, security and technology company, formed in 2001 from
      the
      UK Government's Defence Evaluation &amp; Research Agency (DERA). QinetiQ (QQ.)
      was instrumental in discovering BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">
      and pSivida enjoys a strong relationship with, including access to its cutting
      edge research and development facilities.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      more
      information, visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #0000ff; FONT-FAMILY: Times New Roman"><u>www.psivida.com</u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      document contains forward-looking statements that involve risks and
      uncertainties. The statements reference potential products, applications and
      regulatory approvals. Although we believe that the expectations reflected in
      such forward-looking statements are reasonable at this time, we can give no
      assurance that such expectations will prove to be correct. Given these
      uncertainties, readers are cautioned not to place undue reliance on such
      forward-looking statements. Actual results could differ materially from those
      anticipated in these forward-looking statements due to many important factors
      including: our inability to raise additional funds at favourable terms or any
      terms; our inability to repay the amended debentures; issues relating to share
      registration in the U.S. that may delay our registration; our inability to
      develop proposed products, including without limitation, in the drug delivery,
      wound healing, orthopaedics, and tissue engineering, diagnostics and food
      technology fields; failure of our evaluation agreements to result in license
      agreements; failure to develop applications for BioSilicon&#8482; due to regulatory,
      scientific or other issues; failure to complete negotiations for new centers
      for
      the BrachySil&#8482; phase&#160;IIb clinical trial for inoperable primary liver
      cancer; failure of our discussions with the FDA for BrachySil&#8482; to continue or to
      lead to FDA approval; failure of the BrachySil&#8482; phase&#160;IIb clinical trial
      for inoperable primary liver cancer to determine the optimal dose, provide
      key
      safety data or support future pivotal efficacy trials or product registration
      or
      approval; failure of the BrachySil&#8482; primary liver programme that is in
      phase&#160;IIb clinical trials to&#160;provide a valuable platform for the
      development and commercialisation of BrachySil&#8482; for pancreatic cancer and other
      indications; failure to commence phase&#160;IIa BrachySil&#8482; trials for the
      treatment of pancreatic cancer; failure of the findings&#160;of the pancreatic
      cancer phase&#160;IIa trial to provide a platform for further multicentre
      efficacy and safety trials; failure of there to be optimisation&#160;and
      standardisation between our two&#160; pancreatic cancer&#160;study&#160;centres;
      failure of the results of the Retisert&#8482; for DME trial to be a good indicator of
      the results of pSivida&#8217;s ongoing phase&#160;III Medidur&#8482; for DME trial; failure
      of the Medidur&#8482; trials in DME to show a very similar improvement in visual
      acuity and diabetic retinopathy severity score as Retisert&#8482; for DME; failure of
      Medidur&#8482; to release fluocinolone acetonide at the same rate as Retisert&#8482;; our
      inability to recruit patients for the phase&#160;III Medidur&#8482; for DME
      trial;.&#160;Other reasons are contained in cautionary statements in the Annual
      Report on Form 20-F filed with the U.S. Securities and Exchange Commission,
      including, without limitation, under Item 3.D, "Risk Factors" therein. We do
      not
      undertake to update any oral or written forward-looking statements that may
      be
      made by or on behalf of pSivida.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>psivida_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 psivida_logo.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X0SW17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````;````<@$R``(````4````C8=I``0````!````I````-````!(````
M`0```$@````!061O8F4@4&AO=&]S:&]P($-3(%=I;F1O=W,`,C`P-CHP-#HP
M,R`P,3HP,3HS-0```````Z`!``,````!``$``*`"``0````!````M*`#``0`
M```!````-0`````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0``
M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$```O!````
M`````$@````!````2`````'_V/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B
M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`+P"@`P$B``(1`0,1`?_=``0`
M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`]52253/.36P6TVBMK.6.#8)/T=S[',V)
MF7)[<#/A,N'4B-<5?X7"D"S3;25/%S+<S$+ZMK+VG:X.ES9']4CVN:J#^K9[
M,@T$5%X?LF'1,[?WE6R_$<&.&/(>(PR_)*,;L_N_WDB!-CLZ/4.IX'3,<Y.?
M>VBJ=H+N7./%=;&R^VQW^CK;O68W(^L?5CNQ:QT7!/%N0P69;QIJS$)]##;_
M`.&?6N_[K5HU^#AXESNLY=++^I`>G5:2]VT'39CLN?8S&_X7T/3WHE>3U$T.
MO86WW.&RK'`:&"P_GOOK=8YM-?\`A?S_`/KGIL4OWF'NQQ",CDD.,CT_JX]\
MGJ6&)())J(_=WDT.G?;\;ZT6=/9GWY^(S$];+&1Z;C5<]^W%;6^BNGT_6J9>
M_P!']Q=$J/2>ELZ=0\.L.1E9#S=EY3A#K;3HY^T?S=;&M]*BG_`TL96KRG1$
M4%))*CG]39AN;6UOJ6N$[9@`>94>;-CPP.3)+A@.J\`DT&\DLNGK)]8595)H
MF/<9TGC<UX;[?Y2N9MF373NQ6"RR0-I\._=JCQ\YAR8YY,9,QC^>(C+W(_\`
M4_F48D&CU;"2%C.M?0QUS=EI'O;X'\453QEQ1$A8X@#KH=4*26=U_)ZKB],L
MNZ10,K-:Y@92X2""X"S\^KZ+/Y:GT3(ZCD]+HOZI2,;->#ZU($!I#G!OYUGY
MFW\]%'%ZN'7:_!O)*KU3,.!TW*S@SU#C4ON%<[=VQI?MW>[;NVJA]5NONZ_T
MY^:Z@8Q9<ZK8'[YVACMV[:S_`$B2#,"0C?J(MV4DDDES_]#U5!RP?L[XT($R
M#'&OTMU?_5HRP^M]4R[,IG0>CN#>I7MWWY)&YN)0?:<FQOY^19]##Q_\)9^D
ML_15ILX\<91_>!C_`(R#*M4&[JCV9&-TEU;,K)M:'9-A#A140[U,QC-S_M5S
M/H54^I_/?SWZ-0L;MZCLDN+;6M+G<D@M;O=$>Y_TEK6=(;86/.1=ZK`!ZA=K
M/=W'LW?\'[%CV5N&<:M[G.%H;ZA^E,@;_P"LN=Y^&;#AP89P'##,3CR"0_6<
M4C/Y?T?F9H4297N-NSJ];>TLHJD2ZP.@F-!W[?O*WA2:`XF=Q)!G=I_6WW?]
M6J]/2JFVFYV1;;8-"[?!_JN<WW_]):"U^7P93S&3F,L?;,P(1QWQ^F/64EA(
MH`:J7!9_4_K"_P"OMW2>GYQI98T,K;:`^JN<=MUMS:=/4M9M>^ECW^GZW\Y^
MC7>KSRVVJG_&MOM>VMDM;N<0!N=B;&-EWYSWG8Q7AU\FMS!(&.C5Y(@^27I'
M4.N]'^N8Z'U#.LZACY&F^W7Z5;KZ;JV_X%VZMU-E6[TETO5J+Z<MN=6W>QNT
MGN&EO[_\ARY;-L9D?XT<84D/](L8^-8<RFZRQO\`8:_W+LLCJOV?,&/97MKT
M)MG\TCZ0;'YK_I*E\3CAEAB,TSBN4>#(!?!E_0E+^JOY4FY@>H1E(#^ZPIR>
MG=2<P7U@7-G:QW!GG:?HO1>KVVTX>^IQ8[<T2/!9G5FX;;6/Q'-WF2X5G0$1
ML<-OT7K0ZSN/3AN^EN;/Q5$<Q,X>=A+@.;%$7S&'T^[<?09&/Z<6Q0N)Z'H7
M*^L]W4V_5/[;A9-E.3C[+7V5D;G,G9:UWM=[=K_4_P"MK,SOK1F#Z@8N=7>Y
MF?>YF,;P1O#ZW.]:SCZ5E5#O^W5U5.+7F=%^R6_S>12ZI_P>"QW_`%2\FQ*L
MO+?A_5FUI;MSG"SQ#G;<?)]O_`LINL6MRNN#$3J>"!)/]UI<U*4)FB?U@,!_
M?M[;J&7UC!_Q?U9;\NW]H/%5CLB1O'JV-?L^C^;59Z7T5;Z9UK+H^H8ZO?8<
MC+KHM>'V:[GA]C*O4V[/;NV*7^,$`?57(`$`/I``_P",8LW'8Y_^*UP:)(QK
M''X-M>]W_1:INGU43*.20!/IQ?\`.<KI[?K3G_5SJ76+.JFVAU=U=N)>W>U]
M88?M#ZRW;]EL;[OL_I,V?Z1;/^+JRRGZK9=M59OLKR+G,I:0"]PKJ<VMKG>W
M<_Z*I?5_+QF_XNNI,?:QCF-R:W!Q`.ZQI]%FOYUN[]'^^B_4OJ(Z7]2NH=0+
M/4./?:]K/%VRD,:?Y._Z21Z^;'CH2QRL_P`W*1-VUWX/U_S,7,ZKG9]G378S
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MWRQSB(CP"4#Q1EDC[G"?ZL/E_P`=?$G]+0?NQ_[J3+'=CNJ`QBPU-T&P@@?Y
MJ*HU^GM_1QM_DQ$_)25F/%0XJXNM;)\E+SC,Q<3._P`:%F%F5MNHO;MLJ?J"
M/LF[_HQN:O1T#]1^U?X+[5_9]3C_`+<_FTX&F/+CX^'^K(3_`,5RNB?4[HG1
M,IV7AL>Z\@M8ZUV_8T_2;3QMW?O_`,XM7)P\?*:&W-G;]%PT(^!1TDR<(Y(F
M,XB<3O&0L+XQ$!41P^32Q^DX=#Q8UI>YIEI>9@^,*QDXU637Z5H);(.AC4(J
M2CARV&$#CCCC&$OFB!I+^\NLW=L*:F4U-J9]!@@3JLJCZJ=&Q^LNZU56X9KG
M/L)WN+-U@V6.%?T?=[O\];"2EB!$",10`H`=EIB#1(NC8:?5>EXG5L)^#F!S
MJ+"TN#7%IEI#V^YO\IJ6#TK"P>FLZ92S=B,:YGIV'?+7ESGM?O\`I[MZN)(J
MX1=UK57X/-8_^+SZLX][[A2^PN:YM;+'ES:P\%GZ&?SFM=^C?9ZGIK2Z=]7.
ME=.Z;=TNBLNP\@O-M=CB_=ZC178-SO=]!JTTDK*T8X#:(#S.+_B[^K./<ZXT
MOO)!:QMSR]K-P+?8/;[FM=[/4WK4Z)T#IW0Z;*<`/:RYP>_>\O.X`,_._JK2
M22M4<<(ZB(%/_]G_[1&R4&AO=&]S:&]P(#,N,``X0DE-!"4``````!``````
M````````````````.$))30/M```````0`$@````!``$`2`````$``3A"24T$
M)@``````#@`````````````_@```.$))300-```````$````>#A"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$`````````@`!.$))300"```````$`````#A"24T$"```````
M$`````$```)````"0``````X0DE-!!X```````0`````.$))300:``````-)
M````!@``````````````-0```+0````*`%4`;@!T`&D`=`!L`&4`9``M`#$`
M```!``````````````````````````$``````````````+0````U````````
M``````````````$`````````````````````````$`````$```````!N=6QL
M`````@````9B;W5N9'-/8FIC`````0```````%)C=#$````$`````%1O<"!L
M;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<````U`````%)G
M:'1L;VYG````M`````9S;&EC97-6;$QS`````4]B:F,````!```````%<VQI
M8V4````2````!W-L:6-E241L;VYG``````````=G<F]U<$E$;&]N9P``````
M```&;W)I9VEN96YU;0````Q%4VQI8V5/<FEG:6X````-875T;T=E;F5R871E
M9`````!4>7!E96YU;0````I%4VQI8V54>7!E`````$EM9R`````&8F]U;F1S
M3V)J8P````$```````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F
M=&QO;F<``````````$)T;VUL;VYG````-0````!29VAT;&]N9P```+0````#
M=7)L5$585`````$```````!N=6QL5$585`````$```````!-<V=E5$585```
M``$```````9A;'1486=415A4`````0``````#F-E;&Q497AT27-(5$U,8F]O
M;`$````(8V5L;%1E>'1415A4`````0``````"6AO<GI!;&EG;F5N=6T````/
M15-L:6-E2&]R>D%L:6=N````!V1E9F%U;'0````)=F5R=$%L:6=N96YU;0``
M``]%4VQI8V5697)T06QI9VX````'9&5F875L=`````MB9T-O;&]R5'EP965N
M=6T````115-L:6-E0D=#;VQO<E1Y<&4`````3F]N90````ET;W!/=71S971L
M;VYG``````````IL969T3W5T<V5T;&]N9P`````````,8F]T=&]M3W5T<V5T
M;&]N9P`````````+<FEG:'1/=71S971L;VYG```````X0DE-!"@```````P`
M```!/_`````````X0DE-!!0```````0````".$))300,``````O=`````0``
M`*`````O```!X```6"````O!`!@``?_8_^``$$I&248``0(!`$@`2```_^T`
M#$%D;V)E7T--``'_[@`.061O8F4`9(`````!_]L`A``,"`@("0@,"0D,$0L*
M"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,`0T+"PT.#1`.#A`4#@X.%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"``O`*`#`2(``A$!`Q$!
M_]T`!``*_\0!/P```04!`0$!`0$``````````P`!`@0%!@<("0H+`0`!!0$!
M`0$!`0`````````!``(#!`4&!P@)"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#
M!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#
M)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6
MIK;&UN;V-T=79W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($
M05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$
MDU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]B<W1U=G=X>7I[?'_]H`#`,!``(1`Q$`/P#U5))5,\Y-;!;3:*VLY8X-@D_1
MW/L<S8F9<GMP,^$RX=2(UQ5_A<*0+--M)4\7,MS,0OJVLO:=K@Z7-D?U2/:Y
MJH/ZMGLR#0147A^R8=$SM_>5;+\1P8X8\AXC#+\DHQNS^[_>2($V.SH]0ZG@
M=,QSDY][:*IV@NY<X\5UL;+[;'?Z.MN]9C<CZQ]6.[%K'1<$\6Y#!9EO&FK,
M0GT,-O\`X9]:[_NM6C7X.'B7.ZSETLOZD!Z=5I+W;0=-F.RY]C,;_A?0]/>B
M5Y/430Z]A;?<X;*L<!H8+#^>^^MUCFTU_P"%_/\`^N>FQ2_>8>['$(R.20XR
M/3^KCWR>I88D@DFHC]W>30Z=]OQOK19T]F??GXC,3ULL9'IN-5SW[<5M;Z*Z
M?3]:IE[_`$?W%T2H])Z6SIU#PZPY&5D/-V7E.$.MM.CG[1_-UL:WTJ*?\#2Q
ME:O*=$104DDJ.?U-F&YM;6^I:X3MF`!YE1YLV/#`Y,DN&`ZKP"30;R2RZ>LG
MUA5E4FB8]QG2>-S7AOM_E*YFV9-=.[%8++)`VGP[]VJ/'SF')CGDQDS&/YXB
M,O<C_P!3^91B0:/5L)(6,ZU]#'7-V6D>]O@?Q15/&7%$2%CB`.NAU0I)9W7\
MGJN+TRR[I%`RLUKF!E+A((+@+/SZOHL_EJ?1,CJ.3TNB_JE(QLUX/K4@0&D.
M<&_G6?F;?ST4<7JX==K\&\DJO5,PX'3<K.#/4.-2^X5SMW;&E^W=[MN[:J'U
M6Z^[K_3GYKJ!C%ESJM@?OG:&.W;MK/\`2)(,P)"-^HBW922227/_T/54'+!^
MSOC0@3(,<:_2W5_]6C+#ZWU3+LRF=!Z.X-ZE>W??DD;FXE!]IR;&_GY%GT,/
M'_PEGZ2S]%6FSCQQE']X&/\`C(,JU0;NJ/9D8W275LRLFUH=DV$.%%1#O4S&
M,W/^U7,^A53ZG\]_/?HU"QNWJ.R2XMM:TN=R2"UN]T1[G_26M9TAMA8\Y%WJ
ML`'J%VL]W<>S=_P?L6/96X9QJWN<X6AOJ'Z4R!O_`*RYWGX9L.'!AG`<,,Q.
M/()#]9Q2,_E_1^9FA1)E>XV[.KUM[2RBJ1+K`Z"8T'?M^\K>%)H#B9W$D&=V
MG];?=_U:KT]*J;:;G9%MM@T+M\'^JYS??_TEH+7Y?!E/,9.8RQ]LS`A''?'Z
M8]926$B@!JI<%G]3^L+_`*^W=)Z?G&EEC0RMMH#ZJYQVW6W-IT]2UFU[Z6/?
MZ?K?SGZ-=ZO/+;:J?\:V^U[:V2UNYQ`&YV)L8V7?G/>=C%>'7R:W,$@8Z-7D
MB#Y)>D=0Z[T?ZYCH?4,ZSJ&/D:;[=?I5NOINK;_@7;JW4V5;O272]6HOIRVY
MU;=[&[2>X:6_O_R'+ELVQF1_C1QA20_TBQCXUAS*;K+&_P!AK_<NRR.J_9\P
M8]E>VO0FV?S2/I!L?FO^DJ7Q..&6&(S3.*Y1X,@%\&7]"4OZJ_E2;F!ZA&4@
M/[K"G)Z=U)S!?6!<V=K'<&>=I^B]%ZO;;3A[ZG%CMS1(\%F=6;AMM8_$<W>9
M+A6=`1&QPV_1>M#K.X].&[Z6YL_%41S$SAYV$N`YL41?,8?3[MQ]!D8_IQ;%
M"XGH>A<KZSW=3;]4_MN%DV4Y./LM?961N<R=EK7>UWMVO]3_`*VLS.^M&8/J
M!BYU=[F9][F8QO!&\/K<[UK./I654._[=754XM>9T7[);_-Y%+JG_!X+'?\`
M5+R;$JR\M^']6;6ENW.<+/$.=MQ\GV_\"RFZQ:W*ZX,1.IX($D_W6ES4I0F:
M)_6`P']^WMNH9?6,'_%_5EOR[?V@\56.R)&\>K8U^SZ/YM5GI?15OIG6LNCZ
MACJ]]AR,NNBUX?9KN>'V,J]3;L]N[8I?XP0!]5<@`0`^D`#_`(QBS<=CG_XK
M7!HDC&L<?@VU[W?]%JFZ?51,HY)`$^G%_P`YRNGM^M.?]7.I=8LZJ;:'5W5V
MXE[=[7UAA^T/K+=OV6QON^S^DS9_I%L_XNK+*?JMEVU5F^RO(N<REI`+W"NI
MS:VN=[=S_HJE]7\O&;_BZZDQ]K&.8W)K<'$`[K&GT6:_G6[OT?[Z+]2^HCI?
MU*ZAU`L]0X]]KVL\7;*0QI_D[_I)'KYL>.A+'*S_`#<I$W;7?@_7_,Q<SJN=
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MYXVVW8?1Z3R:`[*O^3K_`$L9G^9:BQD^K8FMNSK=1ZMT_IE3;,ZYM7J';4S5
MUECI`]/'HKW77V>[Z%3%SCGVY66;\H.PJ++`X8H=^L$$_2S+JY;A^W_M+C.^
MT_Z6^K^;6GTKIGU?Z=U%U;<AN7UM[9MMR;FVYA9'[KCOIIV_F4UU5+5'V.-/
M3CRVJIS?+'.(B/`)0/%&62/N<)_JP^7_`!U\2?TM!^['_NI,L=V.ZH#&+#4W
M0;""!_FHJC7Z>W]'&W^3$3\E)68\5#BKBZULGR4O.,S%Q,[_`!H68696VZB]
MNVRI^H(^R;O^C&YJ]'0/U'[5_@OM7]GU./\`MS^;3@:8\N/CX?ZLA/\`Q7*Z
M)]3NB=$RG9>&Q[KR"UCK7;]C3])M/&W=^_\`SBU<G#Q\IH;<V=OT7#0CX%'2
M3)PCDB8SB)Q.\9"POC$0%1'#Y-+'Z3AT/%C6E[FF6EYF#XPK&3C59-?I6@EL
M@Z&-0BI*.'+880....,82^:(&DO[RZS=VPIJ934VIGT&"!.JRJ/JIT;'ZR[K
M55;AFN<^PG>XLW6#98X5_1]WN_SUL)*6($0(Q%`"@!V6F(-$BZ-AI]5Z7B=6
MPGX.8'.HL+2X-<6F6D/;[F_RFI8/2L+!Z:SIE+-V(QKF>G8=\M>7.>U^_P"G
MNWJXDBKA%W6M5?@\UC_XO/JSCWON%+["YKFULL>7-K#P6?H9_.:UWZ-]GJ>F
MM+IWU<Z5T[IMW2Z*R[#R"\VUV.+]WJ-%=@W.]WT&K322LK1C@-H@/,XO^+OZ
MLX]SKC2^\D%K&W/+VLW`M]@]ON:UWL]3>M3HG0.G=#ILIP`]K+G![][R\[@`
MS\[^JM))*U1QPCJ(@4__V0`X0DE-!"$``````%,````!`0````\`00!D`&\`
M8@!E`"``4`!H`&\`=`!O`',`:`!O`'`````2`$$`9`!O`&(`90`@`%``:`!O
M`'0`;P!S`&@`;P!P`"``0P!3`````0`X0DE-!`8```````<`!`````$!`/_A
M%_EH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O`#P_>'!A8VME="!B96=I
M;CTG[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED)S\^"CQX.GAM
M<&UE=&$@>&UL;G,Z>#TG861O8F4Z;G,Z;65T82\G('@Z>&UP=&L])UA-4"!T
M;V]L:VET(#,N,"TR."P@9G)A;65W;W)K(#$N-B<^"CQR9&8Z4D1&('AM;&YS
M.G)D9CTG:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X
M+6YS(R<@>&UL;G,Z:5@])VAT='`Z+R]N<RYA9&]B92YC;VTO:5@O,2XP+R<^
M"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70])W5U:60Z869D-V5E-6$M
M8S)C92TQ,61A+6$W-6,M.#0Y9#@Q-6%C,V-C)PH@('AM;&YS.F5X:68])VAT
M='`Z+R]N<RYA9&]B92YC;VTO97AI9B\Q+C`O)SX*("`\97AI9CI#;VQO<E-P
M86-E/C$\+V5X:68Z0V]L;W)3<&%C93X*("`\97AI9CI0:7AE;%A$:6UE;G-I
M;VX^,3@P/"]E>&EF.E!I>&5L6$1I;65N<VEO;CX*("`\97AI9CI0:7AE;%E$
M:6UE;G-I;VX^-3,\+V5X:68Z4&EX96Q91&EM96YS:6]N/@H@/"]R9&8Z1&5S
M8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70])W5U:60Z
M869D-V5E-6$M8S)C92TQ,61A+6$W-6,M.#0Y9#@Q-6%C,V-C)PH@('AM;&YS
M.G!D9CTG:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R<^"B`\+W)D9CI$
M97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I
M9#IA9F0W964U82UC,F-E+3$Q9&$M83<U8RTX-#ED.#$U86,S8V,G"B`@>&UL
M;G,Z<&AO=&]S:&]P/2=H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q
M+C`O)SX*("`\<&AO=&]S:&]P.DAI<W1O<GD^/"]P:&]T;W-H;W`Z2&ES=&]R
M>3X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2=U=6ED.F%F9#=E935A+6,R8V4M,3%D82UA-S5C+3@T.60X,35A
M8S-C8R<*("!X;6QN<SIT:69F/2=H='1P.B\O;G,N861O8F4N8V]M+W1I9F8O
M,2XP+R<^"B`@/'1I9F8Z3W)I96YT871I;VX^,3PO=&EF9CI/<FEE;G1A=&EO
M;CX*("`\=&EF9CI84F5S;VQU=&EO;CXW,B\Q/"]T:69F.EA297-O;'5T:6]N
M/@H@(#QT:69F.EE297-O;'5T:6]N/C<R+S$\+W1I9F8Z65)E<V]L=71I;VX^
M"B`@/'1I9F8Z4F5S;VQU=&EO;E5N:70^,CPO=&EF9CI297-O;'5T:6]N56YI
M=#X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2=U=6ED.F%F9#=E935A+6,R8V4M,3%D82UA-S5C+3@T.60X,35A
M8S-C8R<*("!X;6QN<SIX87`])VAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"\G/@H@(#QX87`Z0W)E871E1&%T93XR,#`V+3`T+3`S5#`Q.C`Q.C,U+3`U
M.C`P/"]X87`Z0W)E871E1&%T93X*("`\>&%P.DUO9&EF>41A=&4^,C`P-BTP
M-"TP,U0P,3HP,3HS-2TP-3HP,#PO>&%P.DUO9&EF>41A=&4^"B`@/'AA<#I-
M971A9&%T841A=&4^,C`P-BTP-"TP,U0P,3HP,3HS-2TP-3HP,#PO>&%P.DUE
M=&%D871A1&%T93X*("`\>&%P.D-R96%T;W)4;V]L/D%D;V)E(%!H;W1O<VAO
M<"!#4R!7:6YD;W=S/"]X87`Z0W)E871O<E1O;VP^"B`\+W)D9CI$97-C<FEP
M=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#IA9F0W
M964U82UC,F-E+3$Q9&$M83<U8RTX-#ED.#$U86,S8V,G"B`@>&UL;G,Z>&%P
M34T])VAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\G/@H@(#QX87!-
M33I$;V-U;65N=$E$/F%D;V)E.F1O8VED.G!H;W1O<VAO<#IA9F0W964U.2UC
M,F-E+3$Q9&$M83<U8RTX-#ED.#$U86,S8V,\+WAA<$U-.D1O8W5M96YT240^
M"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TG=75I9#IA9F0W964U82UC,F-E+3$Q9&$M83<U8RTX-#ED.#$U86,S
M8V,G"B`@>&UL;G,Z9&,])VAT='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q
M+C$O)SX*("`\9&,Z9F]R;6%T/FEM86=E+VIP96<\+V1C.F9O<FUA=#X*(#PO
M<F1F.D1E<V-R:7!T:6]N/@H*/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"CP_
M>'!A8VME="!E;F0])W<G/S[_X@Q824-#7U!23T9)3$4``0$```Q(3&EN;P(0
M``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@<U)'
M0@``````````````````]M8``0````#3+4A0("``````````````````````
M`````````````````````````````````````````!%C<')T```!4````#-D
M97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"&```
M`!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D```"
MQ````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M96%S
M```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```"`QB
M5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L971T
M+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV-BTR
M+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````````
M````````````````````````````````````````````````6%E:(```````
M`/-1``$````!%LQ865H@`````````````````````%A96B````````!OH@``
M./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$``"V
MSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````
M%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````````
M``````````````````````````````!D97-C`````````"Y)14,@-C$Y-C8M
M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````````
M`"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-2
M1T(`````````````````````````````9&5S8P`````````L4F5F97)E;F-E
M(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````````
M+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$`
M`````````````````````````````````'9I97<``````!.D_@`47RX`$,\4
M``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``````
M```!`````````````````````````H\````"<VEG(`````!#4E0@8W5R=@``
M``````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4`%D`
M7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`Q@#+
M`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%`4P!
M4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!\@'Z
M`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!`LL"
MU0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#QP/3
M`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P!/X%
M#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&609J
M!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E!_@(
M"P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)N@G/
M">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP"\@+
MX0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-^`X3
M#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A$'X0
MFQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3(Q-#
M$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#%B86
M219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`911EK
M&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC',P<
M]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@;""8
M(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-)'PD
MJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$HHBC4
M*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,+4$M
M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ\C(J
M,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I-R0W
M8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\93RD
M/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N0C!"
M<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(!4A+
M2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE3FY.
MMT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4VU4H
M5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N56^5<
M-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB\&-#
M8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(:I]J
M]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R2W*F
M<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&>J5[
M!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"](-7
M@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6B_R,
M8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4])5?
ME<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`GJZ?
M'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H4JC$
MJ3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+LL*S
M.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]%;V/
MO@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_R#W(
MO,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'31-/&
MU$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZBWRG?
MK^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJY>MP
MZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[]XKX
M&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@`.061O8F4`9``````!
M_]L`A``&!`0$!00&!04&"08%!@D+"`8&"`L,"@H+"@H,$`P,#`P,#!`,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0<'!PT,#1@0$!@4#@X.%!0.#@X.
M%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_
MP``1"``U`+0#`1$``A$!`Q$!_]T`!``7_\0!H@````<!`0$!`0``````````
M!`4#`@8!``<("0H+`0`"`@,!`0$!`0`````````!``(#!`4&!P@)"@L0``(!
M`P,"!`(&!P,$`@8"<P$"`Q$$``4A$C%!408382)Q@10RD:$'%;%"(\%2T>$S
M%F+P)'*"\25#-%.2HK)C<\(U1">3H[,V%U1D=,/2X@@F@PD*&!F$E$5&I+16
MTU4H&O+C\\34Y/1E=865I;7%U>7U9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<X
M2%AH>(B8J+C(V.CX*3E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^A$``@(!
M`@,%!00%!@0(`P-M`0`"$0,$(1(Q0051$V$B!G&!D3*AL?`4P='A(T(54F)R
M\3,D-$."%I)3):)CLL('<](UXD2#%U23"`D*&!DF-D4:)V1T53?RH[/#*"G3
MX_.$E*2TQ-3D]&5UA96EM<75Y?5&5F9VAI:FML;6YO9'5V=WAY>GM\?7Y_<X
M2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H`#`,!
M``(1`Q$`/P#U3BKL5=BKL5=BJ0^9O.VA>7C'!=.]QJ5QM::5:*9KN8_Y$2[T
M_P`M^*?Y6$1MHRZB,-C]7\V/U)1%;?F5KP]:YNX?*EB_]W:6Z)>7Q!_W[-)6
M")O\F..3_7P[!J`S3YGPA_IYJ?Y<:CY@EU;S/I>H:@VK6&CW<=M8ZC*B)*SF
M/G-&YC"HWI,56M,,D:6<S*42>*,3Z9?[IG.0<UV*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5__0]4XJA=1FO8;?U+2-)'4U<2,5`0`DFHKF'KLN;'CXL0C,
MCZN,\'H91`)W0FC>8(=1DDMV3TKJ+<I7DK+TY(U!49@=E=M0U4C`C@RP_AOB
MC./\_')E/'P[]$-J7F>XTYZ7.G.J,Q$<GJ*0U.^U:9B:_P!H,FE/[S#(1)/!
M+CCZ^%E#$)<BAQK.H:[:26VGQSV',B-]0A:%GBKU*B566M/\ELGV=V_/5GT8
M9<'%PSGQQ]'_`!3'-@VKBX2@;'2_+GDZ4Q:?`UYK5Y\5[J5W(9+B2O[4T[`M
M3_(7BG^3F1VKV['33&,#CRR\^"&./\Z<FG3:.,18_P!-_'),-7U77SIR6-C#
M&NOWY*6Q!+Q6\6W*ZE.WPQ@_"G^[).$>;'0SRSQ\641A+^@>+T_PL=1(CTP^
MJ7^Q_I)AY9\N6'EW1H-+LN3)'5Y9Y#62:5SRDED;]IY&/)LRR;7%B$(\(33`
MV.Q50O;ZULH#/<R".,;5.Y)\`!U.8VKUF+3PX\AX8LHQ)-!)T\[:*TG$^JJ_
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MT97D7)=BKL5?_]'U3BK3@E&`ZD$9&8L$*PBWF^J^8K2>5RB<']9WY#X55JDE
MI)30?ZV>>:0RAVEB.]S]/JXOZ4?X\N?_`'3ESK@*77_FL>9M._2%M:20:0MR
M8],NY1Q-V@3XYD0_$L7/X8R?M_:S8^VHK'C_`*TON#C:#-XED#T_P_TF1>0O
M]X+G_C+_`,:C)^QG]Q/_`(9_O0W:CF$OE,DWF34'!;DK",%>50!1:?#)$>V:
MK*93[0S2%V#P;<7]7^#+@_F_TF8V@&:K%&K,X4!V`#-W(7IOGHP<2EV*O(+K
M\^+RU\ZZGY<.A/>&SEFM[);1FDGN)HS2->'&BANKM\7!<L\/:W5'M(C(8<-T
MM\J_GGJ]SYTB\L^9]$&DS7,@@BHS\XY7%8UD5Q\0DJ`'7^;"<>UA&'M&1R<$
MX\+,O/PF_P!#._H_'\N6W\,\^]M1/]W_`#/5_I_2]!INJM::7H&K:,D-H$CN
MT1>3T_>*XZEN[`YD:7L[0Z[2"&+AAF$1ZO\`*QR?Q<?\Z/\`L6,IRC+?DG6B
M:4=,L_JWK&8<BP)%`*]0!OMG0=D]F_D\/A\7B;\7\UJR3XC:7V6O>OY@ET_Z
MLB<&D7U@?B/#Z.^:S2=L^)KI8.",>$S_`'G\7H9RQU&[8EJ7YMWVF?FC!Y-O
M--B2SN98HX=0$K<BLZ5C/`K3^\_=_:SJA#:W43UQCF\,C8_Q*GYJ?FU=>3-4
MTW3+'3DU&[OT:0H\ACXU<)&!16KS;E_P.,86G6:TX9"('$9*OYM?F!-Y/TC2
M[J72K?49KR1HY(9FHL;+'R/$\6KOMC"-IUNI\*()'%;)+;S19P>1H/,U[&+:
MU&GI?2PQ[A`8A)P3I7KQ7(UO3D1S`8A,\N'B>6:3^?/F368]0G;RK++H,*.E
MQ=67.:2W#*:&2H"/MNU.'%?BRPXP'68^TISL\'H_HI=_SBU_O?YA_P",-K_Q
M*7#E:^QN<O@RGSQ^><VE^9'\M>6=);6=4A?TIF^,KZH%6CCCC!>0I^V?AXY&
M,-K+E:CM'AGP0'')WD+\\KG6/,R^6O,>DG2=3E8QPLI<#U0.7IR1R`/&6`^$
MU;&6.A81INT3.?!,<,GK65NU?__2]4XJIW-S;VUO)<W$BPP0J9)97(55514L
MQ/0`8H)`%E@-K<IYBTY-=T*SN#:&:06KRI'%S56IS6,*&DAD_89FY?S+G%]L
M]CYL>09<$3.4)>)'@\./A_T?#CCA.?\`RLFV:;4QRQOI_2_B7>8-1N;BSM+>
M?3VL?0)"BA5"`H%$!`H!X9I.W^TLVHQPCEQ2PRB3]7%PS_J\0_XIR<.,1Y%?
MY<U:_L[.>&SL7NI)'J)%!*J>(&]!_')=A=IY\&&4,6*6:4I?5ZN"'I_BX1_O
MHIRP!.Y37R_H=T9&N;^)HY'?U'YF-N;5K]DHS(/]GFZ[%['RF1R9XF,I2\27
M'X<_$G_4\.4\?_*R+5DR#D&49V;CNQ5\Z>3O_6E-1_YBM0_Y-OETOI>?P?XX
M??+_`'S7YNJJ?GIH3H.+,VFLQ'<BY(K]PPP^E==_C,?\W_=/H/4(]/FMVAOB
MGHMU$A"[]B":;YK-=#!/&89N'@E_//"]%$D'9B&L^5[C3`;_`$^9C%%\1WI(
M@\01]H9PG:OL[/1CQ\$CP0W_`-MQ_P"=_$Y4,HEL60>5]7EU*P+3[SPMPD8;
M<MJALZCV=[4EJ\%S_O,9X)?TOYLFC-#A.R1:1_RFUQ_QDG_CG-]F?\;$_P"M
ME_2W3_NP\Z_YR3TV6QU;R_YIMA26)C`[`?MPMZ\-?^2F>DXST>8[6APRC,)<
M;F'SW^?UA+"1+IUDL$P[KPMH1.1_R/?CCRBUV,^J!_AC^/\`=)]_SE'_`,<+
M0_\`F*E_Y-8,3?VQ]$?>G7FPD?\`./`(-/\`</8C[_1&`?4W9O\`%/\`,C_O
M4%_SC^JC\K-28"A:ZN^1\:0H,.3FP[+_`+@^\_<QS_G%K_>[S#_QAM?^)2X<
MKC]C<Y?!D7F?SYY,\N>;9;+REY;BU?SI*[I-+;1A>,LGQ2*TB@O(_>4+_LY%
MR(B2-^3D9M3CQY*QQXLKSHS^9;C\]M(G\RVT-GK$E[9-/;6YJB*57TQ4,^_#
MCR^++-N'9U]S.J!F*E<7U-F.],__T_5.*O-=:DF_,'S1-Y:MG9?*.B2*?,$Z
M$CZW=*>2V:L/]UI]J?\`X'^7)C86Z_(3GGP#^[A]?]*7\QZ1##%#$D,*+'%&
MH2.-0`JJHH``.@`R#G@5LQ?S^0+2T8D!0[DD[``+U)SBO;,7CQ_UI.3I^J'_
M`"^O);FSF:UB+6;R\A>MM&X``_=#K)T^W_=_RL^9WLKHLN#!+Q!P2G+BX?X^
M'A_BC_!_G-.7,)GT[Q_G?P_YO\YF6=.Q=BKL5?+UM<^8+7\^M7N=`M([[4X;
MR^=+.5O3$J!6]1`W[+\*\/\`*R_;AW>:!F-43`<4KE^E,[#1?//GS\VK/7-5
MT2?2+.QF@><3(Z)'%:GF(P[JOJ/(X_9'[7\N)(`;8X\N?.)2CP"/^]>V^;-`
MEU!$N;4<KF$%2G3DG7:O<9QWM+V+/51&3'ODAZ>'^?#_`(J+T^')P[%)I;_S
M5<V7Z,>T<U`1Y/38.5'8L?A^G.?R:WM/-A_+''+^9*?!+CX?Z4OH_P`YM$8`
MW;(O+&CRZ98%9Z>O,W.11N%VH%KG6>SW9<M)@J?]Y,\4OZ/]%HRSXBE6F:??
M1^;I[E[>1;=GF*RE2%(-:;^^:3L_0YH]JSR&$AC,LOKX?1ZOZ39.0X*0GYS>
M6;CS#Y`OK6TA:XO[=H[JTAC')V>-J%5`ZEHV<9WD#1=3K\)R8B!S8/\`\X[^
M1-:T>^U?5M:T^:PG,<=K:)<1F-BK'G(RANWPQC)9)6X796FE`F4APIG_`,Y%
M^7M=UK1]'BTC3Y]0DAN9&E2WC:0JICH"W'IO@QFFWM7%*<1PCBW9-/Y7O=7_
M`"?B\NLA@OY=(@A$4HXE9XXE*J]?L_O%XM@OU6Y)PF6GX.O`'E7Y:7?YJZ%I
M]_Y/L_+$C/=2NPO+Q7AAMFD01NS-3A*E%#+P?_5YY9*CNZO1G/`'&(\_XI?P
MI]_SCKY6\Q:'?Z\=7TVYL4ECMU@>XC:,.4:2O'D-^HR.0@M_96&<#+B!BQ+R
M[9_F#Y`_,'4;E/+5QK4UR9H8Y5CD*2++*'$L<R*ZKRI\=?\`9<<D:(<7%'+@
MS$\)G:,7RW^95]^<.E>8-=T26+G=VDUQ);1L]O#$H4*ID'):QJ*2'E]K&QPT
MR\'-+4"<H]8OH_*'H7__U/3FKW)BM##%,D%[=AX+!I/L_6#&[I_Q`MA##(:'
MF?I2C\OO+8\L^3[#3IP$NTC];4I"P/*YE^.9F?\`:^,TY?RX9&RU:;%X>,`\
M_P"+^LE^K_FIH4-Z=*T&*3S)KAV%CIU'1#XS7']S$H_:);X?Y<1%A/61!X8_
MO)?T?^*05UY6\VZX(KOS,L%TZGG;:)`U+"`]C,6_>7LO^OQMO^*GS4]J'/0_
M+XXSR#Z<N3A_=?U(_P`]LQ83/?*=O]2C]'^?_/\`]RGN@VGF&P=DGMTDCFD5
MI)?4`*@`+L`.@`V7-/V1I^T-/(C)&.3Q9\>3)XGK_I?UG.R&!Y=&29UC0[%7
M8J\=\N?EIYLL?SHO/-=Q#$-&FGO)(Y!*I?C.C!/@Z]3EAD.&G4XM)..H,S]-
MR>Q96[9V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O_]7N7YP#RT?)Y&OF[$7U
MF'ZB=.%;L7>_I^B"0O*G/[1^SDH7;AZ[@\/U7S]/#]7$\P1?)ZF+_'$GG*2Q
MVX'64DCLZ?Y0@>1\LWZ4ZW]W_E/&K_;/H>T^3?\`!GZ'3_"7U/\`1G_+EQX\
MO\OC\7/_`(R?'E1OJ[?!X?#Z*K^BGN!O=BKL5=BKL5=BKL5=BKL5=BKL5=BK
1L5=BKL5=BKL5=BKL5=BK_]D_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
